Loading...
•
Mar 31, 2022
Mirum Pharmaceuticals Q1 2022 Earnings Report
Mirum Pharmaceuticals reported financial results for the first quarter ended March 31, 2022 and provided a business update.
Key Takeaways
Mirum Pharmaceuticals reported a successful first quarter with total revenue of $12.9 million, including $10.9 million from LIVMARLI® product revenue. The company's net loss was $36.6 million, or $1.17 per share, and it had $239.9 million in cash, cash equivalents, and investments as of March 31, 2022.
Total revenue for Q1 2022 was $12.9 million.
Net product revenue for LIVMARLI® was $10.9 million.
The company reported a net loss of $36.6 million, or $1.17 net loss per share.
Mirum had cash, cash equivalents, restricted cash equivalents, and investments of $239.9 million as of March 31, 2022.
Mirum Pharmaceuticals
Mirum Pharmaceuticals
Forward Guidance
Mirum Pharmaceuticals anticipates several milestones in the near future, including topline data from the MARCH-PFIC Phase 3 trial, potential LIVMARLI approval by the European Medicines Agency, interim analysis for VISTAS and OHANA Phase 2b clinical trials, and interim analysis for VANTAGE Phase 2b clinical trial in 2023.